Real-world safety and effectiveness of entrectinib in Japanese patients with ROS1 gene fusion-positive, unresectable, advanced/recurrent non-small cell lung cancer: Post-marketing surveillance

This publication has 15 references indexed in Scilit:

• Survival and medical costs of non‐small cell lung cancer patients according to the first‐line treatment: An observational study using the Kyoto City Integrated Database
  Thoracic Cancer, 2023
• Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
  The Lancet Oncology, 2020
• Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
  The Lancet Oncology, 2020
• The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
  Nature Communications, 2019
• Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
  Annals of Oncology, 2019
• The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non–Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib
  Journal of Thoracic Oncology, 2018
• Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
  Cancer Discovery, 2017
• Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
  Molecular Cancer Therapeutics, 2016
• New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
  European Journal of Cancer, 2009
• Brain metastases and non-small cell lung cancer. Prognostic factors and correlation with survival after irradiation
  Lung Cancer, 2001